Monday, November 30, 2026
3:00 p.m. – 4:00 p.m. ET
Please note this TeleECHO program is 3:00 p.m. Eastern, 2:00 p.m. Central, 1:00 p.m. Mountain and 12:00 p.m. Pacific.
PRESENTING FACULTY
 |
Oren Mason, MD Founder, Attention MD Grand Rapids, Michigan |
PROGRAM OVERVIEW
This case-based ECHO series will help primary care clinicians (including family medicine and internal medicine physicians) confidently manage ADHD from diagnosis to treatment. Participants will review practical evaluation techniques and learn how to diagnose patients by identifying clinical features, comorbidities, and factors driving functional impairment. The program will detail ADHD neurobiology, specifically how dopamine, norepinephrine, and serotonin interact. Finally, it will review the latest clinical evidence for both current and emerging pharmacotherapies, analyzing their strengths and limitations to help clinicians choose the best treatment for their patients. This interactive CME program will bridge the gap between complex neuroscience and practical, evidence-based patient care.
TARGET AUDIENCE
This educational activity is designed for primary care clinicians (including family medicine and internal medicine physicians) and pediatricians who diagnose and manage patients with ADHD across the lifespan.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Implement comprehensive evaluation techniques to identify the broader clinical features of ADHD and factors that influence functional impairment and disease burden
- Identify the neurobiological underpinnings of ADHD including the role of and interplay between dopamine, norepinephrine, and serotonin
- Apply clinical evidence for current and emerging ADHD pharmacotherapies, including their strengths and limitations, to inform treatment selection and comprehensive disease management of ADHD
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education (CE) for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
